Emerging studies suggest Retatrutide , a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a promising development for obesity loss . Preliminary patient investigations have indicated considerable losses in abdominal fat , conceivably outp